Penumbra, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:05 pm EDT
Share
Penumbra, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 270.95 million compared to USD 213.68 million a year ago. Net income was USD 9.21 million compared to net loss of USD 2.27 million a year ago. Basic earnings per share from continuing operations was USD 0.24 compared to basic loss per share from continuing operations of USD 0.06 a year ago. Diluted earnings per share from continuing operations was USD 0.23 compared to diluted loss per share from continuing operations of USD 0.06 a year ago.
For the nine months, sales was USD 773.84 million compared to USD 625.92 million a year ago. Net income was USD 36.74 million compared to net loss of USD 5.88 million a year ago. Basic earnings per share from continuing operations was USD 0.96 compared to basic loss per share from continuing operations of USD 0.16 a year ago. Diluted earnings per share from continuing operations was USD 0.94 compared to diluted loss per share from continuing operations of USD 0.16 a year ago.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA, INC. 
